Is there a role for the no observed adverse effect level in safety pharmacology?
Adversity
NOAEL
No observed adverse effect level
Non-clinical
Safety assessment
Safety pharmacology
Journal
Journal of pharmacological and toxicological methods
ISSN: 1873-488X
Titre abrégé: J Pharmacol Toxicol Methods
Pays: United States
ID NLM: 9206091
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
26
05
2020
revised:
22
06
2020
accepted:
24
06
2020
pubmed:
1
9
2020
medline:
16
7
2021
entrez:
1
9
2020
Statut:
ppublish
Résumé
In nonclinical toxicology the highest dose or exposure without test article-related adverse effects, known as the No Observed Adverse Effect Level (NOAEL), is a variable that may be determined. In safety pharmacology the vast majority of the endpoints measured are quantitative numeric functional endpoints such as changes in heart rate, blood pressure or respiratory frequency, endpoints that are usually not assessed using a defined framework of adversity. Therefore, we asked the question: is there a role for the NOAEL in safety pharmacology? To help answer this question, we conducted a survey via the Safety Pharmacology Society. We found that within safety pharmacology there is no formal definition of adversity and no guidance on defining NOAEL. We also found, perhaps unsurprisingly, there is no agreed rubric for using a NOAEL in safety pharmacology and we learned that the NOAEL is not a requirement in order to progress a new investigational drug through the regulatory process. Thus, a summary label such as NOAEL lacks nuance and disregards context in relation to the nature and the severity of the safety pharmacology findings. Consequently, defining 'adversity' and determining a NOAEL in safety pharmacology studies are not recommended since the range of functional endpoints investigated do not conform to a binary 'toxic/non-toxic' rubric. Focusing on describing test article-related effects on safety pharmacology endpoints, using reasoned arguments as part of an integrated risk assessment, will ensure that the clinical pharmacologists and regulatory bodies see a clear description of relevant findings at each dose or exposure level.
Identifiants
pubmed: 32866658
pii: S1056-8719(20)30246-X
doi: 10.1016/j.vascn.2020.106917
pii:
doi:
Substances chimiques
Drugs, Investigational
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106917Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.